Novartis

News

ESMO: Survival data mars Pluvicto prostate cancer trial

Novartis’ highly-touted radionuclide therapy Pluvicto met its primary endpoint in a phase 3 trial as a second-line therapy for PSMA-positive metastatic castration-resistan

News

Sandoz separates from Novartis, valued at just over $11bn

Sandoz completed its long-heralded separation from Novartis on schedule this morning, with its shares trading at CHF 24 on the SIX Swiss Exchange.

News

Lilly takes POINT in radiopharma push

Eli Lilly has made a foray into the radiopharmaceuticals category with an agreement to buy POINT Biopharma for around $1.4 billion.

News

Novartis adds another string to iptacopan’s bow

Novartis has another phase 3 trial win in its quiver for targeted factor B inhibitor iptacopan, building the case for the drug as a new oral therapy for diseases caused by

News

Polpharma Bio gets first EU okay for Tysabri biosimilar

Polpharma Biologics has said it is the first company to get approval in the EU for a biosimilar version of Biogen’s blockbuster multiple sclerosis therapy Tysabri.

News

Novartis eyes first-line use of Lutathera after trial win

Novartis is preparing to file for approval of its radioligand therapy Lutathera as a first-line treatment for people with rare neuroendocrine tumours after it showed a ben

ESMO: Survival data mars Pluvicto prostate cancer trial

Sandoz separates from Novartis, valued at just over $11bn

Lilly takes POINT in radiopharma push

Novartis adds another string to iptacopan’s bow

Polpharma Bio gets first EU okay for Tysabri biosimilar

Novartis eyes first-line use of Lutathera after trial win

Lilly bags FDA okay for Wegovy pill rival orforglipron

Using AI-driven synthetic personas to take your insights fur...

Novartis

Editor's Picks